Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104625 | 1.00 | ADRB2 (0.41) | ADRB2PDE2ACYP2A6CYP2B6CYP3A4 | |
| SCHEMBL4342752 | 1.00 | ADRB2 (0.41) | ADRB2PDE2ACYP2A6CYP2B6CYP3A4 | |
| SCHEMBL6210422 | 0.83 | FOLH1 (0.33) | ADRB2CYP2A6CYP2B6CYP3A4CYP2C19 | |
| SCHEMBL30144069 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL3513409 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL25489183 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL29974411 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL17000184 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL7999672 | 0.78 | CYP11B2 (0.35) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL29790356 | 0.78 | CYP2A6 (0.38) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | disclosed |
| CN-101679396-B | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2012-06-06 | — | — | CN | disclosed |
| CN-101568539-B | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI | 2012-04-25 | — | — | CN | disclosed |
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8063212-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1846394-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| CN-101679396-A | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| CN-101568539-A | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI (US) | 2009-10-28 | — | — | CN | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | ADRB2 1192/4885PDE2A 2887/4885CYP2A6 3291/4885 |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | ADRB2 1654/4885PDE2A 765/4885CYP2A6 3705/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | ADRB2 95/4885PDE2A 992/4885CYP2A6 209/4885 |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | ADRB2 2818/4885PDE2A 2773/4885CYP2A6 4766/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | ADRB2 3763/4885PDE2A 2651/4885CYP2A6 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.